HIV

March 12th 2025

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a combination antiretroviral therapy (ART) in its long-acting injectable form.

March 12th 2025

When patients switched to either fostemsavir or the combination of dolutegravir/lamivudine (DTG/3TC), suppression was maintained in most patients.

March 11th 2025

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but requires methods of improving adherence to follow-up.

March 10th 2025

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, that has been made in the fight against the HIV pandemic given the current political climate.